Live Video Detailing Scores High Marks with Physicians

Manhattan ResearchThough video detailing had a rocky start when it debuted a decade ago, recent physician online video adoption and satisfaction rates indicate that this channel is now a viable option for pharma, biotech, and device manufacturers. Manhattan Research's ePharma Physician® v8.0 study found that the majority of physicians who have engaged in online video meetings with a pharma sales rep or cell center report that they are satisfied with the experience.

As part of its ePharma Physician® market research and strategic advisory service, Manhattan Research releases a new analysis, "The Evolving Market for Video Detailing: Adoption, Market Potential, and Strategic Implementation." This report includes data and insights around the current state of physician video detailing adoption, demographics, behaviors, and satisfaction; market potential and future interests; delivery models and vendors; and strategic implementation best practices. The objective of the analysis is to provide pharma, biotech, and device manufacturers with the market data and analysis for justifying strategic investment in video detailing and adapting and planning for the future of the physician-sales and company rep relationship.

"Video detailing has finally re-emerged as a viable marketing and service option, prompting manufacturers to take another look at this channel to connect with physicians," said Monique Levy, Senior Director of Research at Manhattan Research and author of the analysis. "Video detailing users are some of the industry's most valuable and tech-savvy customers. Beyond being highly adept at navigating in a multichannel environment, video detailing users are more likely to write a larger volume of scripts and to have a higher weekly patient load than non-users of video detailing."

Analysis Outline
The Evolving Market for Video Detailing: Adoption, Market Potential, and Strategic Implementation

  • Demand for Video Detailing Among U.S. Doctors
  • Profile of Video Detailing Users
  • Outlook
    • Physician Demand
    • Delivery Models and Vendor Overview
  • Strategic Implementation

For an excerpt from the analysis and more information about its contents, please visit: http://www.manhattanresearch.com/products/Research_Modules/Physician/evolving-market-for-video-detailing-pharma.aspx

About ePharma Physician® v8.0
ePharma Physician® v8.0 was conducted via online survey methodology in Q2 2008 among 1,681 online practicing U.S. physicians. The study and advisory service has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit and provides in-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters, society sites, physicians and Web 2.0, physician online communities, electronic detailing, Tablet PCs, online conferences, physician customer service portals, tech-enabled sales forces, physician CRM, and more. For more information: http://www.manhattanresearch.com/products/Strategic_Advisory/ePP/

ePharma Physician® v8.0 reveals the relevant market share and physician satisfaction for 300+ leading pharmaceutical product websites. Broad physician research can by segmented by 25 specialist groups.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...